AnaptysBio (ANAB) Akcija Kursas
AnaptysBio Kursas
Pajamos augo 36,8 % per metus per pastaruosius 12 metus iki 234,60 mln. USD. AnaptysBio grynoji marža dabar yra −5,6 %, išaugo nuo −91,5 % prieš kelerius metus. Analitikų tikslinės kainos mediana yra 75,50 USD, t. y. virš dabartinę kainą 61,9 %. Iš 15 analitikų 14 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
AnaptysBio akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
AnaptysBio akcija ir akcijų analizė
Dažnai užduodami klausimai apie AnaptysBio akciją
The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.
AnaptysBio Inc is primarily active in the biotechnology industry.
The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.
AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.
AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.
AnaptysBio Inc is primarily present in the United States.
AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.
Analitikai šiuo metu nustato vidutinę AnaptysBio akcijos tikslinę kainą 73,67 USD (mediana: 75,50 USD), t. y. +58,0 % palyginti su paskutine kaina. Konsensusas pagrįstas 15 analitikų reitingais.
15 analitikai šiuo metu vertina AnaptysBio akciją: 14 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad AnaptysBio gaus 136,66 mln. USD pajamų ir 2,97 USD pelno akcijai.
Pagal dabartinį kursą AnaptysBio akcija kainuoja 42,47 EUR (46,63 USD).
AnaptysBio akcija (ANAB) kotiruojama 5 biržose, įskaitant: NASDAQ (ANAB), London (0HFQ.L), Frankfurt (AN6.F), München (AN6.MU), Düsseldorf (AN6.DU).
AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.
tikėtina pelnas AnaptysBio yra 136,66 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas AnaptysBio yra 93,24 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) AnaptysBio šiuo metu yra 15,67. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti AnaptysBio akcijos vertę.
Kainų ir pardavimų santykis (KUV) AnaptysBio šiuo metu yra 10,69. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra AnaptysBio akcijos įvertinimo metrika.
Eulerpool kokybės balas AnaptysBio yra 5/10.
AnaptysBio ISIN yra US0327241065. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
AnaptysBio WKN yra A2AJ8C. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
AnaptysBio prekybos žymė yra ANAB. Ši biržos žymė naudojama AnaptysBio akcijoms prekiauti biržoje.
AnaptysBio akcija
AnaptysBio Pagrindiniai konkurentai
AnaptysBio Biržos simbolis
AnaptysBio FIGI
Visos AnaptysBio pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė AnaptysBio akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai AnaptysBio. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: